# Vaxart, Inc.: financial statements, quarterly

VXRT · OTC · CIK 72444 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/vxrt.md) · [Financials](/companies/vxrt/financials.md) · [Filings](/companies/vxrt/filings.md) · [Insiders](/companies/vxrt/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/vxrt/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [2.1](/filings/0001437749-24-034927.md) | [3.2 d](/filings/0001437749-25-008572.md) | [2.2](/filings/0001437749-25-016459.md) | [6.4](/filings/0001437749-25-026514.md) | [4.9](/filings/0001437749-25-034840.md) | [15.2 d](/filings/0001437749-26-008023.md) | [20.9](/filings/0001437749-26-015608.md) | [39.7](/filings/0001437749-26-026289.md) | [72.4](/filings/0001437749-25-034840.md) | [104 d](/filings/0001437749-26-008023.md) | [39.2](/filings/0001437749-26-015608.md) | [27.2](/filings/0001437749-26-026289.md) |
| Cost of revenue | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Research and development | $m | [15.0](/filings/0001437749-24-034927.md) | [14.7 d](/filings/0001437749-25-008572.md) | [19.0](/filings/0001437749-25-016459.md) | [17.5](/filings/0001437749-25-026514.md) | [15.1](/filings/0001437749-25-034840.md) | [22.7 d](/filings/0001437749-26-008023.md) | [30.7](/filings/0001437749-26-015608.md) | [49.7](/filings/0001437749-26-026289.md) | [75.9](/filings/0001437749-25-034840.md) | [45.2 d](/filings/0001437749-26-008023.md) | [29.4](/filings/0001437749-26-015608.md) | [33.8](/filings/0001437749-26-026289.md) |
| Selling, general and administrative | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Operating income | $m | [(17.8)](/filings/0001437749-24-034927.md) | [(16.9) d](/filings/0001437749-25-008572.md) | [(24.1)](/filings/0001437749-25-016459.md) | [(16.3)](/filings/0001437749-25-026514.md) | [(14.5)](/filings/0001437749-25-034840.md) | [(11.5) d](/filings/0001437749-26-008023.md) | [(14.9)](/filings/0001437749-26-015608.md) | [(14.6)](/filings/0001437749-26-026289.md) | [(7.8)](/filings/0001437749-25-034840.md) | [55.4 d](/filings/0001437749-26-008023.md) | [5.2](/filings/0001437749-26-015608.md) | [(13.2)](/filings/0001437749-26-026289.md) |
| Interest expense | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Income tax | $m | [0.0](/filings/0001437749-24-034927.md) | [0.2 d](/filings/0001437749-25-008572.md) | [0.0](/filings/0001437749-25-016459.md) | [0.0](/filings/0001437749-25-026514.md) | [0.0](/filings/0001437749-25-034840.md) | [0.2 d](/filings/0001437749-26-008023.md) | [0.1](/filings/0001437749-26-015608.md) | [0.0](/filings/0001437749-26-026289.md) | [0.0](/filings/0001437749-25-034840.md) | [0.3 d](/filings/0001437749-26-008023.md) | [0.0](/filings/0001437749-26-015608.md) | [0.0](/filings/0001437749-26-026289.md) |
| Net income | $m | [(17.4)](/filings/0001437749-24-034927.md) | [(17.4) d](/filings/0001437749-25-008572.md) | [(24.4)](/filings/0001437749-25-016459.md) | [(16.5)](/filings/0001437749-25-026514.md) | [(14.1)](/filings/0001437749-25-034840.md) | [(12.0) d](/filings/0001437749-26-008023.md) | [(15.6)](/filings/0001437749-26-015608.md) | [(15.0)](/filings/0001437749-26-026289.md) | [(8.1)](/filings/0001437749-25-034840.md) | [55.0 d](/filings/0001437749-26-008023.md) | [5.2](/filings/0001437749-26-015608.md) | [(13.5)](/filings/0001437749-26-026289.md) |
| Diluted EPS | $ per share | not reported | not reported | not reported | not reported | not reported | not reported | [(0.07)](/filings/0001437749-26-015608.md) | not reported | not reported | not reported | [0.02](/filings/0001437749-26-015608.md) | not reported |
| Basic EPS | $ per share | [(0.11)](/filings/0001437749-24-034927.md) | not reported | [(0.14)](/filings/0001437749-25-016459.md) | [(0.09)](/filings/0001437749-25-026514.md) | [(0.06)](/filings/0001437749-25-034840.md) | not reported | [(0.07)](/filings/0001437749-26-015608.md) | [(0.07)](/filings/0001437749-26-026289.md) | [(0.04)](/filings/0001437749-25-034840.md) | not reported | [0.02](/filings/0001437749-26-015608.md) | [(0.06)](/filings/0001437749-26-026289.md) |

- Revenue: us-gaap:Revenues
- Cost of revenue: not reported
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: not reported
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: not reported
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [33.2](/filings/0001437749-24-034927.md) | [34.8](/filings/0001437749-24-007865.md) | [26.7](/filings/0001437749-24-016236.md) | not reported | [22.0](/filings/0001437749-24-034927.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Current assets | $m | [57.1](/filings/0001437749-23-030009.md) | [45.5](/filings/0001437749-25-008572.md) | [44.3](/filings/0001437749-24-016236.md) | [71.5](/filings/0001437749-24-025556.md) | [66.5](/filings/0001437749-24-034927.md) | [68.3](/filings/0001437749-26-008023.md) | [62.6](/filings/0001437749-25-016459.md) | [70.4](/filings/0001437749-25-026514.md) | [117](/filings/0001437749-25-034840.md) | [136](/filings/0001437749-26-026289.md) | [132](/filings/0001437749-26-015608.md) | [117](/filings/0001437749-26-026289.md) |
| Total assets | $m | [106](/filings/0001437749-23-030009.md) | [91.8](/filings/0001437749-25-008572.md) | [88.7](/filings/0001437749-24-016236.md) | [114](/filings/0001437749-24-025556.md) | [167](/filings/0001437749-24-034927.md) | [166](/filings/0001437749-26-008023.md) | [159](/filings/0001437749-25-016459.md) | [164](/filings/0001437749-25-026514.md) | [209](/filings/0001437749-25-034840.md) | [186](/filings/0001437749-26-026289.md) | [180](/filings/0001437749-26-015608.md) | [165](/filings/0001437749-26-026289.md) |
| Current liabilities | $m | [11.3](/filings/0001437749-23-030009.md) | [13.7](/filings/0001437749-25-008572.md) | [14.1](/filings/0001437749-24-016236.md) | [15.8](/filings/0001437749-24-025556.md) | [80.4](/filings/0001437749-24-034927.md) | [90.9](/filings/0001437749-26-008023.md) | [98.5](/filings/0001437749-25-016459.md) | [118](/filings/0001437749-25-026514.md) | [169](/filings/0001437749-25-034840.md) | [86.8](/filings/0001437749-26-026289.md) | [76.8](/filings/0001437749-26-015608.md) | [73.1](/filings/0001437749-26-026289.md) |
| Total liabilities | $m | [34.1](/filings/0001437749-23-030009.md) | [34.0](/filings/0001437749-25-008572.md) | [33.0](/filings/0001437749-24-016236.md) | [33.7](/filings/0001437749-24-025556.md) | [98.2](/filings/0001437749-24-034927.md) | [107](/filings/0001437749-26-008023.md) | [113](/filings/0001437749-25-016459.md) | [131](/filings/0001437749-25-026514.md) | [182](/filings/0001437749-25-034840.md) | [98.3](/filings/0001437749-26-026289.md) | [85.9](/filings/0001437749-26-015608.md) | [82.8](/filings/0001437749-26-026289.md) |
| Long-term debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [71.5](/filings/0001437749-24-034927.md) | [57.8](/filings/0001437749-26-008023.md) | [55.7](/filings/0001437749-25-026514.md) | [80.0](/filings/0001437749-25-034840.md) | [68.4](/filings/0001437749-25-034840.md) | [58.9](/filings/0001437749-26-026289.md) | [45.6](/filings/0001437749-26-026289.md) | [32.9](/filings/0001437749-26-026289.md) | [26.8](/filings/0001437749-25-034840.md) | [87.8](/filings/0001437749-26-026289.md) | [94.1](/filings/0001437749-26-026289.md) | [82.4](/filings/0001437749-26-026289.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: not reported
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(15.0) d](/filings/0001437749-24-034927.md) | [(13.5) d](/filings/0001437749-25-008572.md) | [(21.2)](/filings/0001437749-25-016459.md) | [(12.0) d](/filings/0001437749-25-026514.md) | [(4.2) d](/filings/0001437749-25-034840.md) | [(7.3) d](/filings/0001437749-26-008023.md) | [(9.6)](/filings/0001437749-26-015608.md) | [(15.9) d](/filings/0001437749-26-026289.md) | [2.6 d](/filings/0001437749-25-034840.md) | [30.7 d](/filings/0001437749-26-008023.md) | [(2.1)](/filings/0001437749-26-015608.md) | [2.8 d](/filings/0001437749-26-026289.md) |
| Capital expenditure | $m | [0.3 d](/filings/0001437749-24-034927.md) | [(0.1) d](/filings/0001437749-25-008572.md) | [0.1](/filings/0001437749-25-016459.md) | [0.4 d](/filings/0001437749-25-026514.md) | [0.0 d](/filings/0001437749-25-034840.md) | [0.0 d](/filings/0001437749-26-008023.md) | [0.1](/filings/0001437749-26-015608.md) | [(0.1) d](/filings/0001437749-26-026289.md) | [0.1 d](/filings/0001437749-25-034840.md) | [0.0 d](/filings/0001437749-26-008023.md) | [0.4](/filings/0001437749-26-015608.md) | [0.0 d](/filings/0001437749-26-026289.md) |
| Share repurchases | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Share repurchases: not reported

## Shares

| Line item | Unit | Q1 FY2016 (2015-09-30) | Q2 FY2016 (2015-12-31) | Q3 FY2016 (2016-03-31) | Q1 FY2017 (2016-09-30) | Q2 FY2017 (2016-12-31) | Q3 FY2017 (2017-03-31) | Q1 FY2017 (2017-09-30) | Q2 FY2017 (2017-12-31) | Q1 FY2018 (2018-03-31) | Q1 FY2019 (2019-03-31) | Q1 FY2025 (2025-03-31) | Q1 FY2026 (2026-03-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [38.6](/filings/0001437749-16-041405.md) | [38.6](/filings/0001437749-17-001767.md) | [38.6](/filings/0001437749-17-008297.md) | [38.6](/filings/0001437749-17-018561.md) | [38.6](/filings/0001437749-18-001749.md) | [0.1](/filings/0001513162-18-000133.md) | [38.6](/filings/0001437749-17-018561.md) | [38.6](/filings/0001437749-18-001749.md) | [5.3](/filings/0001437749-19-009292.md) | [7.3](/filings/0001437749-19-009292.md) | [228](/filings/0001437749-26-015608.md) | [242](/filings/0001437749-26-015608.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 242,835,358 at 2026-07-31, from the cover of the [10-Q filed 2026-08-06](/filings/0001437749-26-026289.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:19 ET. No prices; not investment advice.